Zydus Lifesciences Ltd. announced on Wednesday that the company has received final approval from the United States Food and Drug Administration to market Sacubitril and Valsartan tablets.
The Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The pharmaceutical firm will manufacture the drug at the group’s formulation manufacturing facility in Moraiya, Ahmedabad, according to an exchange filing.
The company now has 399 approvals and over 460 abbreviated new drug application approvals from the FDA since the commencement of the filing process.
Earlier on July 4, the pharmaceutical firm had received tentative approval from the US FDA for a hypertension drug—Azilsartan medoxomil tablet, which is a angiotensin II receptor blocker that is used to treat hypertension and lower blood pressure.
Shares of Zydus Lifesciences closed 1.61% higher at Rs 1,185 per share, as compared to a 0.53% decline in the Sensex.
RECOMMENDED FOR YOU
Shilpa Medicare's US Customer Gets Fast Track Approval For Glioblastoma Drug
Oct 16, 2024
Biocon Biologics' Insulin Facility Gets Eight Observations Post US FDA Inspections
Oct 07, 2024
Alembic Pharma Gets US FDA Nod For Generic Medication To Treat Seizure
Oct 03, 2024
Zydus Lifesciences Gets U.S. FDA Nod To Produce Generic Prostate Cancer Drug
Sep 28, 2024
POPULAR